|
Market Closed -
Euronext Paris
11:55:00 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 0.3000 EUR | +1.69% |
|
-2.91% | +0.67% |
| 09-16 | Nicox to present NCX 470 data at a conference |  |
| 09-11 | Chinese Regulator Accepts Nicox's Glaucoma Drug Application for Review | MT |
Company Valuation: Nicox SA
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 109.8 | 55.83 | 22.05 | 19.32 | 24.12 | 26.44 | - |
| Change | - | -49.18% | -60.51% | -12.36% | 24.81% | 9.63% | - |
| Enterprise Value (EV) | 89.38 | 53.61 | 31.68 | 19.32 | 24.12 | 26.44 | 26.44 |
| Change | - | -40.02% | -40.9% | -39.01% | 24.81% | 9.63% | 0% |
| P/E | -2.18x | -1.78x | -1.05x | -0.88x | -9.93x | -6x | 15x |
| PBR | 1.45x | 1.04x | - | - | - | - | - |
| PEG | - | 0x | 0x | 0x | 0.1x | -0.1x | -0x |
| Capitalization / Revenue | 15.2x | 17.1x | 5.25x | 2.46x | 1.44x | 8.81x | 2.64x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 8.81x | 2.64x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | 0x | -5.29x | 13.2x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -1.17 | -0.63 | -0.42 | -0.32 | -0.03 | -0.05 | 0.02 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 7.233 | 3.271 | 4.2 | 7.859 | 16.77 | 3 | 10 |
| EBITDA | -16.61 | -22.86 | -17.04 | - | - | - | - |
| EBIT 1 | -46.01 | -33.96 | -17.06 | -9.854 | 4.626 | -5 | 2 |
| Net income 1 | -43.76 | -27.76 | -20.88 | -22.39 | -2.413 | -5 | 2 |
| Net Debt | -20.46 | -2.216 | 9.636 | - | - | - | - |
| Reference price 2 | 2.5550 | 1.1200 | 0.4420 | 0.2810 | 0.2980 | 0.3000 | 0.3000 |
| Nbr of stocks (in thousands) | 42,991 | 49,845 | 49,882 | 68,764 | 80,926 | 88,131 | - |
| Announcement Date | 4/28/22 | 3/20/23 | 4/22/24 | 4/29/25 | 4/30/26 | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6x | - | - | - | 29.74M | |
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | |
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | |
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | |
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | |
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | |
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | |
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | |
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | |
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | |
| Average | 25.55x | 6.95x | 18.39x | 2.15% | 394.09B | |
| Weighted average by Cap. | 34.72x | 8.20x | 20.04x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALCOX Stock
- Valuation Nicox SA
Select your edition
All financial news and data tailored to specific country editions
